ArticleJournal of applied clinical medical physics2026
Treatment strategy in stereotactic radiosurgery for trigeminal neuralgia, essential tremor, and coexisting intracranial tumors: The impact of biologically effective dose on clinical outcome.
Article in Journal of applied clinical medical physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Role of radiosurgical thalamotomy in the management for essential tremor: evidence from an international multi-institutional study.Journal of neurology · 2026Article
- Treatment strategy in stereotactic radiosurgery for trigeminal neuralgia, essential tremor, and coexisting intracranial tumors: The impact of biologically effective dose on clinical outcome.Journal of applied clinical medical physics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGamma Knife radiosurgery (GKRS) is a well-established treatment for trigeminal neuralgia (TN) and essential tremor (ET). In patients with coexisting intracranial tumors, radiosurgery can potentially address functional and oncologic targets in a single or staged session. However, data on integrating these treatments and the predictive role of the biologically effective dose (BED), remain limited. This study aims to evaluate clinical outcomes and identify the influence of dosimetric predictors, including BED, in patients undergoing GKRS for TN and/or ET in the context of coexisting intracranial tumors.
methodsThis retrospective analysis included 12 patients treated with GKRS for TN and a coexisting intracranial tumor, and two patients treated for ET and a tumor. Clinical outcomes were assessed using Barrow Neurological Institute (BNI) pain and numbness scores. Treatment parameters, including prescribed dose, dose rate, and BED, were analyzed. BED thresholds for response prediction were identified using logistic regression and receiver operating characteristic (ROC) analysis.
resultsClinically meaningful pain relief was observed in 76.5% of all GKRS treatment sessions, including instances where patients underwent repeat GKRS. Among 12 analyzable TN patients (15 treatment sessions), five underwent repeat GKRS for recurrent or persistent pain. Of the patients with available imaging, 50% showed tumor shrinkage, while the remainder were radiological non-responders; two of these three patients were among the five who required repeat GKRS. Repeat treatments were well-tolerated, with no increase in complications or radiation necrosis. BED was significantly associated with early BNI improvement across the cohort (Spearman's ρ = 0.660, p = 0.0054; Pearson's r = 0.718, p = 0.0017, R
conclusionGKRS is safe and effective for TN in patients with intracranial tumors. BED appears to be a valuable predictor of early treatment response, particularly in tumor-related TN, where it demonstrated enhanced predictive strength. These findings support integrating BED into treatment planning and highlight the broader utility of radiosurgery in addressing coexisting functional and oncologic pathologies. Prospective studies are warranted to validate these observations and optimize dose-guided strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.